NuCana (NCNA) Stock: Buy, Sell, or Hold?
NCNA - NuCana plc American Depositary Share
$1.09
-0.08 (-6.84%)
▼
5d:
-14.84%
30d:
-21.58%
90d:
-21.58%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When NCNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NCNA is down 14.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NCNA is down 14.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NCNA is currently trading at $1.09, which is considered oversold relative to its 30-day fair value range of $1.26 to $1.48.
Technical Outlook: Technically, NCNA is in a strong downtrend. Immediate support is located at $0.95, while resistance sits at $1.44. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: NCNA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $104.00 (+9441.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NCNA is in a strong downtrend. Immediate support is located at $0.95, while resistance sits at $1.44. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: NCNA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $104.00 (+9441.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.26 -
$1.48
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.8%)
- BULLISH: Trading 9441.3% below Wall St target ($104.00)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.26 -
$1.48
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.95
Resistance Level
$1.44
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.96
Wall Street Target
$104.00
(+9441.3%)
Share & Embed Analysis
Last updated: October 04, 2026 2:16 AM ET
Data refreshes hourly during market hours. Next update: 3:16 AM
Data refreshes hourly during market hours. Next update: 3:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NCNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
